Alimemazine
chemical compound
Alimemazine (INN), also known as trimeprazine, commonly provided as a tartrate salt, is a phenothiazine derivative that is used as an antipruritic (it prevents itching from causes such as eczema or poison ivy, by acting as an antihistamine). It also acts as a sedative, hypnotic, and antiemetic for prevention of motion sickness.
Despite being structurally related to the molecule chlorpromazine, it is not used as an antipsychotic.
Society and culture
Brand names
Brand names include Nedeltran, Panectyl, Repeltin, Teraligen, Therafene, Theraligene, Theralen, Thegalin, Theralene, Vallergan, Vanectyl, and Temaril.
Use by Country
In the Russian Federation, it is sold under the brand name Teraligen for the treatment of anxiety disorders (including GAD), organic mood disorders, sleep disturbances, personality disorders accompanied by asthenia and depression, somatoform autonomic dysfunction and various neuroses.
Veterinary use
In the United States, the Food and Drug Administration (FDA) has not approved it for human use, and it can only be prescribed by veterinarians.
A novel combination drug that combines alimemazine with prednisolone and sold under the brand name Temaril-P is licensed as an antipruritic and antitussive in dogs (called Vanectyl P in Canada). A generic version of the combination trimeprazine/prednisolone was approved by the US Food and Drug Administration (FDA) in June 2024.
This brief starts where responsible research should: with the source description of “Alimemazine” as chemical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 28, 2026. The linked authority identifier is Q2623251. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Alimemazine”, its source revision and the description used here.
- Expand the search: follow Alimemazine primary sources, Alimemazine archive and Alimemazine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Alimemazine”?
- Which observation, specimen, dataset or publication supports the account?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Alimemazine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.